Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder
NCT06107062Phase 2Recruiting
- Sponsor
- University of Colorado Boulder
- Start
- Jul 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in cannabis use disorder (CUD) (3 arms), sponsored by University of Colorado Boulder. Primary endpoints: Difference in cannabis use at 8 weeks, Difference in symptoms of cannabis use disorder (CUD) at 8 weeks and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT06107062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107062.